Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Heidel, Florian H., Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Candoni, Anna, Leber, Brian, Sekeres, Mikkael A., Pollyea, Daniel A., Ferdinand, Roxanne, Ma, Weidong Wendy, O’Brien, Thomas, O’Connell, Ashleigh, Chan, Geoffrey, Heuser, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362563/
https://www.ncbi.nlm.nih.gov/pubmed/32664995
http://dx.doi.org/10.1186/s13045-020-00929-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362563/
https://www.ncbi.nlm.nih.gov/pubmed/32664995
http://dx.doi.org/10.1186/s13045-020-00929-8

Ejemplares similares